Drug–drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults

References

• Albekairy A, Alkatheri A, Fujita S, Hemming A, Howard R, Reed A, Karlix J. 2013. Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. Saudi J Gastroenterol. 19(2):89–95.
   PubMed Web of Science ®Google Scholar
• Alessiani M, Cillo U, Fung JJ, Irish W, Abu-Elmagd K, Jain A, Takaya S, Van Thiel D, Starzl TE. 1993. Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc. 25(1 Pt 1):628–634.
   PubMed Web of Science ®Google Scholar
• Almond LM, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O, Tay S, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A, et al. 2016. Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab Dispos. 44(6):821–832.
   PubMed Web of Science ®Google Scholar
• Bittersohl H, Schniedewind B, Christians U, Luppa PB. 2018. A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. J Chromatogr A. 1547:45–52.
   PubMed Web of Science ®Google Scholar
• Chen L, Lu X, Tan G, Zhu L, Liu Y, Li M. 2020. Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. Xenobiotica; The Fate of Foreign Compounds in Biological Systems. 50(2):196–191.
   Web of Science ®Google Scholar
• Cochrane SM, Parent JM, Black WD, Allen DG, Lumsden JH. 1990. Pharmacokinetics of phenobarbital in the cat following multiple oral administration. Can J Vet Res. 54(3):309–312.
   PubMed Web of Science ®Google Scholar
• Emoto C, Johnson TN, Hahn D, Christians U, Alloway RR, Vinks AA, Fukuda T. 2019. A Theoretical physiologically-based pharmacokinetic approach to ascertain covariates explaining the large interpatient variability in tacrolimus disposition. CPT Pharmacometrics Syst Pharmacol. 8(5):273–284.
   PubMedGoogle Scholar
• Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J. 1991. Adverse effects associated with the use of FK 506. Transplant Proc. 23(6):3105–3108.
   PubMed Web of Science ®Google Scholar
• McLaughlin GE, Rossique-Gonzalez M, Gelman B, Kato T. 2000. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant Proc. 32(3):665–668.
   PubMed Web of Science ®Google Scholar
• Hardwick LL, Batiuk TD. 2002. Severe prolonged tacrolimus overdose with minimal consequences. Pharmacotherapy. 22(8):1063–1066.
   PubMed Web of Science ®Google Scholar
• Jogiraju VK, Avvari S, Gollen R, Taft DR. 2017. Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. Biopharm Drug Dispos. 38(7):426–438.
   PubMed Web of Science ®Google Scholar
• Lange NW, Salerno DM, Berger K, Tsapepas DS. 2017. Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations. Clin Transplant. 31(11):e13098.
   Web of Science ®Google Scholar
• Li CJ, Li L. 2015. Tacrolimus in preventing transplant rejection in Chinese patients-optimizing use. Drug Des Devel Ther. 9:473–485.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Han D, Wang Z, Zhang L, Yang S, Wang Q, Wen H, Fan H. 2019. Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: two case reports. J Int Med Res. 47(12):6397–6403.
   PubMed Web of Science ®Google Scholar
• Marfo K, Altshuler J, Lu A. 2010. Tacrolimus pharmacokinetic and pharmacogenomic differences between adults and pediatric solid organ transplant recipients. Pharmaceutics. 2(3):291–299.
   PubMedGoogle Scholar
• May DG, Porter J, Wilkinson GR, Branch RA. 1994. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther. 55(5):492–500.
   PubMed Web of Science ®Google Scholar
• Michael E, Burton LMS, Jerome J. 2005. Applied pharmacokinetics and pharmacodynamics. New York (NY): Lippincott Williams & Wilkins.
   Google Scholar
• Michalets EL. 1998. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 18(1):84–112.
   PubMed Web of Science ®Google Scholar
• Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. 1995. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metabol Dispos: The Biological Fate of Chemicals. 23(10):1110–1116.
   PubMed Web of Science ®Google Scholar
• Peters DH, Fitton A, Plosker GL, Faulds D. 1993. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 46(4):746–794.
   PubMed Web of Science ®Google Scholar
• Quirós-Tejeira RE, Chang I-F, Bristow LJ, Karpen SJ, Goss JA. 2005. Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient. Pediatr Transplant. 9(6):792–796.
   PubMed Web of Science ®Google Scholar
• Rainer WGG, David ERS, Drangstveit MB, Troppmann C, Angelika CG. 1996. Use of FK 506 in pancreas transplantation. Transplant Int. 9(s1):S251–S257.
   PubMedGoogle Scholar
• Renner FC, Staak A, Orde LBA, Walmrath HD, Weimer R. 2007. Tacrolimus intoxication resolved by gastrointestinal bleeding: case report. Transplant Proc. 39(2):522–525.
   PubMed Web of Science ®Google Scholar
• Renton KW. 2001. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther. 92(2-3):147–163.
   PubMed Web of Science ®Google Scholar
• Siddiqi N, Marfo K. 2010. Clinically significant drug–drug interaction between tacrolimus and phenobarbital: the price we pay. J Pharm Pract. 23(6):585–589.
   PubMedGoogle Scholar
• Sun JY, Xu ZJ, Sun F, Guo HL, Ding XS, Chen F, Xu J. 2018. Individualized tacrolimus therapy for pediatric nephrotic syndrome: considerations for ontogeny and pharmacogenetics of CYP3A. Curr Pharm Des. 24(24):2765–2773.
   PubMed Web of Science ®Google Scholar
• Viswanathan CT, Booker HE, Welling PG. 1978. Bioavailability of oral and intramuscular phenobarbital. J Clin Pharmacol. 18(2–3):100–105.
   PubMed Web of Science ®Google Scholar
• Wallemacq PE, Verbeeck RK. 2001. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 40(4):283–295.
   PubMed Web of Science ®Google Scholar
• Wallemacq PE, Furlan V, Möller A, Schäfer A, Stadler P, Firdaous I, Taburet AM, Reding R, Clement De Clety S, De Ville De Goyet J, et al. 1998. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 23(3):367–370.
   PubMed Web of Science ®Google Scholar
• Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R. 1991. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc. 23(6):3153–3155.
   PubMed Web of Science ®Google Scholar
• Xin H-W, Wu X-C, Li Q, Yu A-R, Zhu M, Shen Y, Su D, Xiong L. 2007. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol. 64(4):469–475.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al. 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 71(15):732–739.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Lu C. 2016. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 6(5):430–440.
   PubMed Web of Science ®Google Scholar